CIK 0001936258 · Large accelerated filer
NewAmsterdam Pharma Co N.V.
Sign in to watch- Ticker
- NAMS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Netherlands
- Entity type
- operating
- Phone
- 35 206 2971
- Business address
- GOOIMEER 2-35, NARRDEN, Netherlands, 1411 DC
- Former names
- NewAmsterdam Pharma Co B.V.
Securities
- NAMS Ordinary Shares Nasdaq
- NAMSW Warrant Nasdaq
- Open-market buys, last 90 days
- $226,500
- in 1 filing
- Open-market sales, last 90 days
- $4,661,919
- in 3 filings, $4.6M under 10b5-1 plans
Net −$4,435,419. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-30 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Option exercise 10b5-1 | +50,246 | 119,548 | ||
| 2026-09-30 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Sale 10b5-1 | −50,246 | $25.03 | $1.3M | 69,302 |
| 2026-09-30 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Option exercise · Option (right to buy) 10b5-1 | −50,246 | 344,983 | ||
| 2026-09-14 | Davidson Michael H. Chief Executive Officer | Purchase | +10,000 | $22.65 | $227K | 792,923 |
| 2026-09-04 | Smither John W Director | Sale | −1,600 | $25.32 | $41K | 8,760 |
| 2026-09-01 | Gunning Robert William Vice President, Controller | Grant or award | +3,200 | 3,200 | ||
| 2026-09-01 | Gunning Robert William Vice President, Controller | Grant or award · Option (right to buy) | +14,000 | 14,000 | ||
| 2026-08-24 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Option exercise 10b5-1 | +125,000 | 194,302 | ||
| 2026-08-24 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Sale 10b5-1 | −125,000 | $26.91 | $3.4M | 69,302 |
| 2026-08-24 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Option exercise · Option (right to buy) 10b5-1 | −125,000 | 395,229 | ||
| 2026-07-20 | Kooij Louise Frederika Chief Accounting Officer | Option exercise 10b5-1 | +25,000 | $11.90 | $298K | 49,353 |
| 2026-07-20 | Kooij Louise Frederika Chief Accounting Officer | Option exercise 10b5-1 | +80,000 | $11.17 | $894K | 129,353 |
| 2026-07-20 | Kooij Louise Frederika Chief Accounting Officer | Sale 10b5-1 | −70,200 | $29.96 | $2.1M | 59,153 |
| 2026-07-20 | Kooij Louise Frederika Chief Accounting Officer | Sale 10b5-1 | −31,885 | $31.05 | $990K | 27,268 |
| 2026-07-20 | Kooij Louise Frederika Chief Accounting Officer | Sale 10b5-1 | −2,915 | $31.71 | $92K | 24,353 |
| 2026-07-20 | Kooij Louise Frederika Chief Accounting Officer | Option exercise · Option (right to buy) 10b5-1 | −25,000 | 10,000 | ||
| 2026-07-20 | Kooij Louise Frederika Chief Accounting Officer | Option exercise · Option (right to buy) 10b5-1 | −80,000 | 70,494 | ||
| 2026-06-22 | Kooij Louise Frederika Chief Accounting Officer | Option exercise 10b5-1 | +25,000 | $10.90 | $273K | 49,353 |
| 2026-06-22 | Kooij Louise Frederika Chief Accounting Officer | Option exercise 10b5-1 | +15,000 | $11.90 | $179K | 64,353 |
| 2026-06-22 | Kooij Louise Frederika Chief Accounting Officer | Sale 10b5-1 | −39,700 | $30.20 | $1.2M | 24,653 |
Page 1 of 15 · 300 trades